Navigation Links
Our Lady of Lourdes Medical Center & The Heart House Participating in Research Study Using Adult Stem Cells for Chronic Cardiac Condition
Date:6/12/2013

Camden, New Jersey (PRWEB) June 12, 2013

Our Lady of Lourdes Medical Center and The Heart House are participating in a clinical study to determine whether a patient’s own (autologous), adult, stem cells are safe and can relieve chronic chest pain caused by coronary artery disease, as well as increase their ability to walk/exercise.

The RENEW study, sponsored by Baxter Healthcare Corporation and endorsed by the FDA to support a Biologic License Application for investigational CD34+ cell therapy, is a Phase III clinical trial to test the safety and efficacy of CD34+ stem cells. The study is being conducted at only 50 sites in North America and will involve approximately 440 patients.

The Principal Investigator, Vijay Verma, MD, FACC, and Sub-Investigator Andrew Zinn, MD, both interventional cardiologists with Cardiovascular Associates of the Delaware Valley (The Heart House), performed the first procedure at Our Lady of Lourdes Medical Center on April 25, 2013. The patient suffers from severe refractory angina, with two of the three arteries that supply oxygen to the heart completely blocked and is unable to undergo conventional revascularization.

“The patient suffers chest pain every day due to the blockages,” said Dr. Verma. “She has exhausted all other optimal therapies, including angioplasty, bypass surgery and enhanced external counter pulsation (EECP) to relieve the persistent chest pain.”

Patients enrolled in the study are randomly assigned to undergo the procedure or receive the standard of care. Patients in the procedure group are blindly randomized to receive either the stem cells or a placebo.

Forty-eight hours prior to the procedure, Dr. Verma conducted Apheresis procedure to selectively withdraw cells from the patient’s bloodstream. These cells were sent to a special lab where CD34+ cells were extracted and sent back to the hospital for injection into the patient’s heart. Derived from bone marrow, CD34+ cells are comprised of endothelial progenitor cells, which may be able to regenerate heart tissue and develop into new blood vessels. Previous Phase I & Phase II clinical trials have shown that the administration of the CD34+ cells were safe, and a reduction in chest pain and increased ability to exercise was noted in people with myocardial ischemia, or lack of oxygen flow to the heart tissue.

During the nearly four-hour procedure, Dr. Verma and his team created an electrical map of the patient’s heart to locate the damaged area they believed might be causing the chest pain. Using a catheter threaded through the patient’s groin area to the heart, Dr. Verma injected the patient’s CD34+ stem cells into areas of heart muscle with poor blood circulation. Neither Dr. Verma nor the patient knows if the stem cells or a placebo were injected until after the trial is completed and data has been obtained and evaluated.

“We will follow her for the next two years to see whether the injections improve her chest pain and her tolerance to exercise,” said Dr. Verma.

To learn if you are eligible to participate in the study, visit http://www.renewstudy.com.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10825425.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lourdes Doctors Urge Testing During Hepatitis Awareness Month
2. Lourdes Specialty Hospital Offers Unique Treatment Option for Medically Complex Patients with Hyperbaric Oxygen Therapy
3. Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend
4. Physician Groups Call for Fewer Medical Tests
5. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
6. CAM therapy combined with conventional medical care may improve treatment of lower back pain
7. Image share project gives patients and physicians anytime, anywhere access to medical images
8. Researchers determine vitamin D blood level for reducing major medical risks in older adults
9. Biomedical researchers receive Hartwell Foundation awards
10. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
11. Fitness in Middle Age Lowers Medical Costs Later: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... , ... July 27, 2017 , ... Team Novo Nordisk, ... Brand to the men’s pro squad as a stagiaire for the remainder of the ... professional debut on July 31st at the Tour of Utah. , “Every season we ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley ... major advancement in drug therapy for patients living with relapsing and primary multiple ... novel B cell targeted therapy that has been proven to significantly reduce signs ...
(Date:7/26/2017)... ... 26, 2017 , ... “We are dentists and we thought there could be ... “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending MAGNETIC/ LOCK BRACKETS provides ... so, it offers an effective alternative to traditional braces. As a result, it enhances ...
(Date:7/26/2017)... Baton Rouge, Louisiana (PRWEB) , ... July 26, 2017 , ... ... their doctors to offer the ability for patients to schedule an appointment online in ... LocalMed directly from the Six Month Smiles provider directory will bring more Six Month ...
(Date:7/26/2017)... ... ... M. Musielak, a partner at the Andrew Cores Family Law Group, a division ... earlier this year. She will serve the membership in this capacity for a term of ... the organization’s by-laws. , Musielak joined the Andrew Cores Family Law Group ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... July 14, 2017 Endo International plc (NASDAQ: ... August 8, 2017.  Members of its senior management team will host ... at 8:30 a.m. ET. The dial-in number to ... International (678) 509-7598, and the passcode is 45397076. Please dial in ... A replay of the call will be ...
(Date:7/13/2017)... York City-based market research firm Kalorama Information notes seven trends ... new products to new costs, to the threat of generic ... Potential Pipeline Disruptors . Among them are ... Age-Driven Growth - True Impact Moment Arriving   ... growing population and, to a more extreme extent, the aging ...
(Date:7/11/2017)...  Bayer has awarded grants totaling more than $2 million ... prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and ... and Uniformed Services University of the Health Sciences in ... recipients were announced last night during a reception at the ... Berlin, Germany . ...
Breaking Medicine Technology: